Abstract: A non-woven hydroentangled textile is described formed in cross-section with a central area of low mass fiber density surrounded on both sides by areas of higher mass density. Further, a personal cleansing article is described wherein the hydroentangled textile is associated with a personal cleansing composition that includes a lathering surfactant. The composition is deposited onto, impregnated into or at least is partially enclosed by the textile. Also described is a process for producing the textile involving feeding into a hydroentangling unit a loose random assembly of fibers both above and below a fibrous screen modifying textile substrate.

Abstract: A non-woven hydroentangled textile is described formed in cross-section with a central area of low mass fiber density surrounded on both sides by areas of higher mass density. Further, a personal cleansing article is described wherein the hydroentangled textile is associated with a personal cleansing composition that includes a lathering surfactant. The composition is deposited onto, impregnated into or at least is partially enclosed by the textile. Also described is a process for producing the textile involving feeding into a hydroentangling unit a loose random assembly of fibers both above and below a fibrous screen modifying textile substrate.

Abstract: A non-woven hydroentangled textile is described formed in cross-section with a central area of low mass fiber density surrounded on both sides by areas of higher mass density. Further, a personal cleansing article is described wherein the hydroentangled textile is associated with a personal cleansing composition that includes a lathering surfactant. The composition is deposited onto, impregnated into or at least is partially enclosed by the textile. Also described is a process for producing the textile involving feeding into a hydroentangling unit a loose random assembly of fibers both above and below a fibrous screen modifying textile substrate.

Abstract: The present invention relates to high dose oral liquid formulations of bisphosphonate and their methods of use to treat/prevent diseases related to bone remodeling or bone disorders, such as for example, Paget's disease, osteoporosis, metastatic bone disease, hypercalcemia of malignancy, periprosthetic osteolysis, periodontal disease, arthritic conditions, and the like, while minimizing the potential for esophageal irritation and other adverse gastrointestinal effects. These methods comprise orally administering to a mammal in need thereof a pharmaceutically effective amount of the liquid pharmaceutical composition of at least one bisphosphonate, or a pharmaceutically acceptable salt thereof, as a unit dosage according to a continuous schedule having a once-weekly, twice-weekly, biweekly, twice-monthly, or monthly dosing interval. The present invention also relates to liquid pharmaceutical compositions of the bisphosphonate for carrying out these methods.

Abstract: A pharmaceutical composition is disclosed which contains a compound of formula I: ##STR1## or a pharmaceutically acceptable salt, prodrug or hydrate thereof, in the stabilized form and/or in combination with a carbon dioxide source.